Suppr超能文献

CCL2/CCR2轴影响急性髓系白血病细胞的迁移和增殖,但不影响其对化疗的耐药性。

The CCL2/CCR2 Axis Affects Transmigration and Proliferation but Not Resistance to Chemotherapy of Acute Myeloid Leukemia Cells.

作者信息

Macanas-Pirard Patricia, Quezada Thomas, Navarrete Leonardo, Broekhuizen Richard, Leisewitz Andrea, Nervi Bruno, Ramírez Pablo A

机构信息

Hematology Oncology Department, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.

Institute of Medicine, Faculty of Medicine, Universidad Austral de Chile, Valdivia, Región de los Ríos, Chile.

出版信息

PLoS One. 2017 Jan 3;12(1):e0168888. doi: 10.1371/journal.pone.0168888. eCollection 2017.

Abstract

Acute myeloid leukemia (AML) has a high mortality rate despite chemotherapy and transplantation. Both CXCR4/SDF-1 and VLA-4/VCAM1 axes are involved in leukemia protection but little is known about the role of CCL2/CCR2 in AML biology and protection against chemotherapy. We measured CCR2 expression in AML cell lines and primary AML cells by flow cytometry (FCM), real time PCR (RT-PCR) and western blot (WB). CCL2 production was quantified by solid phase ELISA in peripheral blood (PB) and bone marrow (BM) serum. We measured chemotaxis in a transwell system with different concentrations of CCL2/CCR2 blockers; cell cycle with BrDU and propidium iodide and proliferation with yellow tetrazolium MTT. We determined synergy in in vitro cell apoptosis combining chemotherapy and CCL2/CCR2 blockade. Finally, we performed chemoprotection studies in an in vivo mouse model. Of 35 patients, 23 (65%) expressed CCR2 by FCM in PB. Two cell lines expressed high levels of CCR2 (THP-1 and murine AML). RT-PCR and WB confirmed CCR2 production. CCL2 solid phase ELISA showed significantly lower levels of CCL2 in PB and BM compared to normal controls. Chemotaxis experiments confirmed a dose-dependent migration in AML primary cells expressing CCR2 and THP-1 cells. A significant inhibition of transmigration was seen after CCL2/CCR2 blockade. Proliferation of CCR2+ AML cell lines was slightly increased (1.4-fold) after axis stimulation. We observed a non-significant increase in phase S THP-1 cells exposed to CCL2 and a concomitant decrease of cells in G1. The chemotherapy studies did not show a protective effect of CCL2 on cytarabine-induced apoptosis or synergy with chemotherapy after CCL2/CCR2 blockade both in vitro and in vivo. In conclusion, CCL2/CCR2 axis is expressed in the majority of monocytoid AML blasts. The axis is involved in cell trafficking and proliferation but no in vitro and in vivo chemotherapy protective effect was seen.

摘要

尽管进行了化疗和移植,急性髓系白血病(AML)的死亡率仍然很高。CXCR4/SDF-1和VLA-4/VCAM1轴均参与白血病的保护过程,但关于CCL2/CCR2在AML生物学特性及化疗保护中的作用却知之甚少。我们通过流式细胞术(FCM)、实时聚合酶链反应(RT-PCR)和蛋白质免疫印迹法(WB)检测了AML细胞系和原发性AML细胞中CCR2的表达。通过固相酶联免疫吸附测定法(ELISA)对外周血(PB)和骨髓(BM)血清中的CCL2生成量进行定量。我们在具有不同浓度CCL2/CCR2阻滞剂的Transwell系统中检测趋化性;用溴脱氧尿苷(BrDU)和碘化丙啶检测细胞周期,用黄色四氮唑MTT检测细胞增殖。我们在体外细胞凋亡实验中确定了化疗与CCL2/CCR2阻断联合使用的协同作用。最后,我们在体内小鼠模型中进行了化学保护研究。35例患者中,23例(65%)外周血中的原始细胞通过流式细胞术检测显示表达CCR2。两种细胞系均高表达CCR2(THP-1和鼠AML)。RT-PCR和WB证实了CCR2的生成。固相ELISA显示,与正常对照组相比,外周血和骨髓中的CCL2水平显著降低。趋化性实验证实,表达CCR2的AML原代细胞和THP-1细胞存在剂量依赖性迁移。CCL2/CCR2阻断后,迁移明显受到抑制。轴刺激后,CCR2+AML细胞系的增殖略有增加(1.4倍)。我们观察到,暴露于CCL2的THP-1细胞S期有不显著增加,同时G1期细胞减少。化疗研究表明,无论是在体外还是体内,CCL2对阿糖胞苷诱导的细胞凋亡均无保护作用,且在CCL2/CCR2阻断后与化疗也无协同作用。总之,CCL2/CCR2轴在大多数单核细胞样AML原始细胞中表达。该轴参与细胞转运和增殖,但未观察到体外和体内化疗保护作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f310/5207636/355c04719159/pone.0168888.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验